

THE EUROPEAN SOCIETY OF PATHOLOGY (ESP)

Title: Recent Advances and Updates in Histopathology

Saturday, February 29, 2020
7:00 PM – 10:00 PM

Moderators:

Holger Moch, MD, PhD, University Hospital Zürich, Zürich, Switzerland

Dina Tiniakos, MD, PhD, Aretaieion Hospital, National & Kapodistrian University of Athens, Athens, Greece *and* Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

Course Description:

The 2nd European Society of Pathology Companion Meeting will highlight recent developments and updates in histopathology of head and neck, breast, renal cancers, neuroendocrine neoplasms, soft tissue sarcoma and different types of thyroiditis.

The selected topics will be presented by expert faculty with diagnostic and research expertise in these fields. Although characterization and classification of many tumors via the well-established histomorphology remains the gold standard in the interpretation of such diseases, the use of new diagnostic algorithms and integration of molecular genetics in diagnosis have an essential role in unraveling diagnostic and research challenges. This close bond has a substantial impact on characterizing disease entities, improving diagnostic accuracy, identifying molecular predictive and prognostic markers and discovery and validation of novel therapeutic molecular targets.

Learning Objectives:

Upon completion of this educational activity, the learner will be able to:

- Appreciate the impact of human papilloma viruses and translocations on the prognosis of head and neck cancers, particularly those of the oropharynx and sinonasal tract, and the potential implications for patient management.
- Define the histomorphological and immunophenotypic features of Ductal carcinoma in situ (DCIS) and their impact on disease recurrence and progression and surgical and clinical management. Integration and use of molecular tests will be discussed.
- Recognize the commonalities and differences of neuroendocrine neoplasms
- Describe criteria and diagnostic algorithms how to classify different types of thyroiditis in a clinically relevant way and understand the clinical- morphologic correlation in pathogenesis of thyroid inflammations.
- Recognize how and when to integrate molecular genetics in sarcoma diagnostics.
- Approach oncocytic neoplasms in the kidney

7:00 PM	<p>Recent advances in the molecular pathology of head and neck cancers</p> <p>Tim Helliwell, MD, PhD, Department of Cellular Pathology, Duncan Building Royal Liverpool University Hospital Prescot Road, Liverpool, United Kingdom</p>
7:30 PM	<p>Ductal <i>in situ</i> carcinoma of the breast: pathological diagnosis and clinical impact</p> <p>Anna Sapino, MD, PhD, Direttrice Dip. di Scienze Mediche, Università degli Studi di Torino, Torino, Italy</p>
8:00 PM	<p>Neuroendocrine neoplasms: Two families with distinct features unified in one classification</p> <p>Günter Klöppel, MD, PhD, Consultation Center for Pancreatic and Endocrine Tumors, Institute of Pathology, Technical University of Munich, Munich, Germany</p>
8:30 PM	<p>Everything you always wanted to know about thyroiditis but were afraid to ask</p> <p>Aleš Ryška, MD, PhD, Charles University Medical Faculty Hospital, The Fingerland Department of Pathology, Hradec Kralove, Czech Republic</p>
9:00 PM	<p>Soft Tissue sarcomas in the era of the NGS epidemics</p> <p>Angelo Paolo Dei Tos, MD, PhD, University of Padua School of Medicine, Department of Pathology, Treviso, Italy</p>
9:30 PM	<p>Chromophobe renal cell carcinoma- Time for new groupings?</p> <p>Holger Moch, MD, PhD, University Hospital Zürich, Zürich, Switzerland</p>

References

1. You EL, Henry M, Zeitouni AG. Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management. *Curr Oncol.* 2019 Apr;26(2):119–123.
2. Bishop JA. Newly described tumor entities in sinonasal tract pathology. *Head Neck Pathol* 2016;10:23–31.
3. Agaimy A, Weichert W. SMARCA4-deficient sinonasal carcinoma. *Head Neck Pathol* 2017, 11, 541–545.
4. Hanna WM, Parra-Herran C, Lu FI, et al. Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies. *Mod Pathol.* 2019;32(7):896–915.
5. Sanati S. Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. *The American Journal of Pathology.* 2019;189(5):947–955.
6. Castellano I, Marchiò C, Tomatis M, et al. Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. *Mod Pathol.* 2010;23(2):260–9.

7. Atsuko Kasajima, Björn Konukiewitz, Naomi Oka, et al. Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20%. *Neuroendocrinology*, 2018
8. Guido Rindi, David S. Klimstra, Behnoush Abedi-Ardekani, et al. A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Modern Pathology* 2018
9. Günter Klöppel. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. *Visc Med* 2018
10. Jokisch F, Kleinlein I, Haller B, et al. A small subgroup of Hashimoto's thyroiditis is associated with IgG4-related disease. *Virchows Arch.* 2016 Mar;468(3):321–7.
11. Imblum BA, Baloch ZW, Fraker D, LiVolsi VA. Pembrolizumab-Induced Thyroiditis. *Endocr Pathol.* 2019 Jun;30(2):163–167.
12. Fellegara G, Rosai J. Multifocal fibrosing thyroiditis: report of 55 cases of a poorly recognized entity. *Am J Surg Pathol.* 2015 Mar;39(3):416–24.
13. Neuville A, Ranchère-Vince D, Dei Tos AP, et al. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study. *Am J Surg Pathol.* 2013 Aug;37(8):1259–68.
14. Rossi S, Gasparotto D, Miceli R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naïve localized GIST: a population-based study. *Am J Surg Pathol.* 2015 Jul;39(7):922–30.
15. Schaefer IM, Cote GM, Hornick JL. Contemporary Sarcoma Diagnosis, Genetics, and Genomics. *J Clin Oncol.* 2018 Jan 10;36(2):101–110.
16. Ohashi R, Schraml P, Angori S, et al. Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype. *Cancers* in press
17. Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? *Histopathology* 2019, 75, 174–184.
18. Brunelli M, Delahunt B, Gobbo S, et al. Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses. *Am J Clin Pathol* 2010, 133, 116–126.

Target Audience: This course is suitable for residents in pathology, attending pathologists, and is also appropriate for biomedical scientists involved in the field of pathology.

Business Meeting: The ESP plans to organise a business meeting following the course